The Histamine Pathway is a Target to Treat Hepatic Experimental Erythropoietic ProtoporphyriaSummary

Background & Aims: Erythropoietic protoporphyria (EPP) is caused by mutations in ferrochelatase, which inserts iron into protoporphyrin-IX (PP-IX) to generate heme. EPP is characterized by PP-IX accumulation, skin photosensitivity, cholestasis, and end-stage liver disease. Despite available drug...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ning Kuo, Pei Li, Juliana Bragazzi Cunha, Lu Chen, Jordan A. Shavit, M. Bishr Omary
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-01-01
Edice:	Cellular and Molecular Gastroenterology and Hepatology
Témata:	Anti-H1 Histamine Blocker Anti-H2 Histamine Blocker Ferrochelatase Porphyria-related Liver Disease
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2352345X25000049
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!